Bear discusses studies adding treatments to chemotherapy in order to increase the pathological complete response (pCR) rate and the difficulties of translating those benefits into better overall survival (OS) rates for patients with breast cancer.
Harry Bear, MD, PhD, chair, Surgical Oncology, Virginia Commonwealth University Health, discusses studies adding treatments to chemotherapy in order to increase the pathological complete response (pCR) rate and the difficulties of translating those benefits into better overall survival (OS) rates for patients with breast cancer. Bear says in order to impact OS, the treatment a patient is given must greatly impact their pCR.
Pembrolizumab/Olaparib Did Not Improve Survival in Locally Advanced or Metastatic TNBC
December 6th 2023Maintenance pembrolizumab plus olaparib did not improve progression-free or overall survival in patients with locally recurrent inoperable or metastatic triple-negative breast cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Capivasertib Shows Superior PROs Vs Placebo in HR+, HER2- Breast Cancer
December 6th 2023Patient-reported outcomes of the CAPItello-291 study of capivasertib plus fulvestrant showed a positive benefit-risk profile for the combination in patients with HR-positive, HER2-negative advanced breast cancer.
Read More